// App-Quantinova.ai

PO1001 : Acute Declines in eGFR During Treatment with Canagliflozin (CANA) and Its Implications for Clinical Practice: Insights from CREDENCE

Researchers

Presenter

  • L Heerspink HiddoJan

Principal Investigators

  • Jardine MegJ

  • Agarwal Rajiv

  • Bakris GeorgeL

  • Cannon ChristopherP

  • Charytan DavidM

  • de Zeeuw Dick

  • Edwards Robert

  • Greene Tom

  • Levin Adeera

  • Mahaffey KennethW

  • Neal Bruce

  • Pollock CarolA

  • Rosenthal Norm

  • Wheeler DavidC

  • Zhang Hong

  • Zinman Bernard

  • Perkovic Vlado

Medical Centers

  • The George Inst. for Global Hlth., Sydney, Australia

  • The George Institute for Global Health, Sydney, NewSouth Wales, Australia

  • Indiana University School of Medicine and VA Medical Center Indianapolis Indiana United States

  • Cardiovascular Division Baim Institute for Clinical Research Boston Massachusetts United States

  • Nephrology Division NYU School of Medicine and NYU Langone Medical Center New York New York United States

  • Department of Pathology, University of Groningen, University Medical Center Groningen,, Groningen, Netherlands

  • Janssen Research & Development, Raritan, New Jersey, United States

  • Division of Biostatistics, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, United States

  • Division of Nephrology University of British Columbia Vancouver British Columbia Canada

  • Stanford Center for Prevention Research, Stanford University School of Medicine, Stanford, California, United States

  • Kolling Institute of Medical Research Sydney Medical School University of Sydney Royal North Shore Hospital St Leonards New South Wales Australia

  • Department of Renal Medicine, UCL Medical School, London, LoNDON, United Kingdom

  • Renal Division of Peking University First Hospital Beijing China

  • Lunenfeld-Tanenbaum Research Institute of Sinai Health System, University of Toronto, Toronto, Ontario, Canada

Locations

  • Australia

  • United States

  • Netherlands

  • Canada

  • United Kingdom

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

  • Genetic Disorder

Disease

  • Type 2 diabetes mellitus

Biomarkers

  • N/A

Drug/Treatment

  • Canagliflozin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved